IP Library Granted Patent US 11,278,589
Granted Patent B2
US 11,278,589 · App. 15/761,825 · Granted Mar 22, 2022

Use of a cyclic tripeptide for improving cellular energy metabolism

Inventors: Jean-Philippe Wolf (Paris, FR); Anne Lombes (Paris, FR); Morgane Bomsel (Paris, FR)
Assignees: ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS; UNIVERSITE DE PARIS; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MÉDICALE (INSERM); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
A61K38/12A61K8/64A61K9/0014A61K9/0048A61P15/08B63B21/00C07K5/0812C07K7/64C07K14/705B63B2021/004
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,278,589
App. No.
15/761,825
Granted
Mar 22, 2022
Kind
B2
Abstract

The present invention relates to the use of a cyclic peptide comprising the tripeptide reproducing a binding site of fertilin beta to the oocyte integrin, for improving cellular energy metabolism. More particularly, the invention concerns the use of a cyclic peptide comprising the tripeptide FEEc for stimulating the energy metabolism of gametes or embryonic cells in the context of medically assisted procreation (MAP) protocols, in particular promoting the in vitro maturation of the oocyte, the fertilization rate and the birth rate.

Claims (10)

1. A method of maturating immature mammalian oocytes in vitro comprising:

contacting the immature mammalian oocytes in vitro with at least one cyclic peptide comprising a cyclic tripeptide F-E-E of SEQ ID NO: 1 with a cyclization linkage between the two end cysteines, thereby maturating the mammalian oocytes.

2. The method of claim 1 , wherein the immature mammalian oocytes are human oocytes.

3. The method of claim 1 , wherein the immature mammalian oocytes are incubated with 1 to 100 μM of cyclic peptide for a period of between 1 minute and 4 days.

4. The method of claim 1 , wherein contacting the immature mammalian oocytes with the cyclic peptide decreases the risks of miscarriage.

5. The method of claim 1 , wherein contacting the immature mammalian oocytes with the cyclic peptide decreases the risks of aneuploidy in the oocyte.

6. The method of claim 5 , wherein the aneuploidy is trisomy.

7. The method of claim 1 , wherein the immature mammalian oocytes are human oocytes from a woman 37 years old or older.

8. The method of claim 1 , wherein the immature mammalian oocytes are human oocytes from a woman under the age of 30.

9. The method of claim 1 , wherein contacting the immature mammalian oocytes with the at least one cyclic peptide improves ploidy of oocytes.

Assignments (4)
CHANGE OF NAME Recorded Mar 25, 2022
From: UNIVERSITÉ DE PARIS
To: UNIVERSITÉ PARIS CITÉ
Reel/Frame 059504/0225 →
MERGER Recorded Jul 22, 2021
From: UNIVERSITE DE PARIS DESCARTES
To: UNIVERSITE DE PARIS
Reel/Frame 056958/0603 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF THIRD ASSIGNEE PREVIOUSLY RECORDED AT REEL: 048021 FRAME: 0744. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Dec 9, 2020
From: WOLF, JEAN-PHILIPPE; LOMBES, ANNE; BOMSEL, MORGANE
To: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS; UNIVERSITE PARIS DESCARTES; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MÉDICALE (INSERM); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Reel/Frame 054661/0648 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 16, 2019
From: WOLF, JEAN-PHILIPPE; LOMBES, ANNE; BOMSEL, MORGANE
To: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS; UNIVERSITE PARIS DESCARTES; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Reel/Frame 048021/0744 →
Priority Claims (1)
FR 1558899 · Sep 21, 2015 · national
Continuity (1)
Related Publication 20180264075A1 · Sep 20, 2018